Eisai slashes full-year guidance on weakness for Aricept and Halaven
This article was originally published in Scrip
Executive Summary
The main take-away from Eisai's third-quarter results was the major downward revision in sales and profit forecasts for the full fiscal year on much weaker than expected sales of key products Aricept and Halaven.